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Decentralized, bedside, or point of care analysis of
nucleic acids (DNA/RNA/mRNA/microRNA)-based
markers is expected to be a key component of digital
healthcare. Nucleic acids-based approaches allow for
screening of disease and pathogens, disease surveillance,
selection of treatment, treatment effectiveness, differen-
tial diagnosis, risk assessment, staging, and prognosis.
Hand-held genetic analysis systems have the potential to
provide all these capabilities in a simple, affordable, field
deployable, rapid, multiplexed, and robust manner without
the need for electrical power or refrigerated reagents. Even
the need for specific language can be eliminated by trans-
latable or visual graphical user interface truly integrating
the analytical system with the communication network.
The presentation will introduce Gene-Z and iDx, two
networkable platforms that are developed to provide sim-
plified analysis of genetic markers. Gene-Z has Android/
iPod based operation using BluetoothTM and capable of
carrying out quantitative isothermal amplification for 64
reactions in a disposable microfluidic chip. The device is
battery operated and can be charged by solar panels inte-
grated at the top of the device. A smaller version (iDx)
working as an attachment to cell phones, also with real
time amplification and quantification capabilities, allows 8
reactions in parallel. Both these devices are networkable
and currently being validated for a number of key applica-
tions important to human and animal health, plant safety,
industrial microbiology, and environmental protection.
Simplification, reliability, and cost-effectiveness are key
factors ensuring successful implementation of such
approaches. Business model for adoption of such low cost
approaches, however, is still evolving and major challenges
need to be addressed about how to sustain a business that
is built on small margins usually by small companies
engaged in biomedical research.
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